Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatment

observed. Since that time, Italian residents are slowly reorganizing their lives, including work, social, and private activities. The number of new primary melanomas detected from January 1, 2019, to May 9, 2019, was 141 and 115 in Rome and Reggio Emilia, respectively, while in the same timeframe in 2020, they were 62 and 28. These data can be read in two ways: first, patients feared to present to the hospital for the risk of infection with SARS-CoV-2; second, melanoma incidence is not decreasing but melanomas “stayed at home,” just to name a popular hashtag of this pandemic. After May 4, all patients were rescheduled with longer time for visits (from 15-20 minutes to 30-45 minutes) to guarantee social distancing, sanitization, and stopping at checkpoint before entering. As the number of COVID patients decrease, it seems that people are more prone to attend a visit, although data are still lacking. We envision that melanoma diagnosis will increase remarkably in the upcoming months, although it is unpredictable whether this delay related to the pandemic might affect Breslow thickness and patients’ prognosis. Specific and tailored population campaign should be considered to emphasize the fact that although aggressive and contagious, COVID-19 is not the only cause of death and that cancer and melanoma need to be diagnosed and promptly cured.